These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20022493)

  • 1. Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
    Reger TS; Zunic J; Stock N; Wang B; Smith ND; Munoz B; Green MD; Gardner MF; James JP; Chen W; Alves K; Si Q; Treonze KM; Lingham RB; Mumford RA
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1173-6. PubMed ID: 20022493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
    Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.
    Chang LL; Yang GX; McCauley E; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1688-91. PubMed ID: 18242984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists.
    Rehman A; Soni A; Naik K; Nair S; Palle VP; Dastidar S; Ray A; Alam MS; Salman M; Cliffe IA; Sattigeri V
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5514-20. PubMed ID: 20705461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and binding properties of a fluorescent α₉β₁/α₄β₁ integrin antagonist and its application as an in vivo probe for bone marrow haemopoietic stem cells.
    Cao B; Hutt OE; Zhang Z; Li S; Heazlewood SY; Williams B; Smith JA; Haylock DN; Savage GP; Nilsson SK
    Org Biomol Chem; 2014 Feb; 12(6):965-78. PubMed ID: 24363056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
    Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists.
    Hagmann WK
    Curr Top Med Chem; 2004; 4(14):1461-71. PubMed ID: 15544537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.
    Hagmann WK; Durette PL; Lanza T; Kevin NJ; de Laszlo SE; Kopka IE; Young D; Magriotis PA; Li B; Lin LS; Yang G; Kamenecka T; Chang LL; Wilson J; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LA; Kidambi U; Lyons K; Vincent S; Stearns R; Colletti A; Teffera J; Tong S; Fenyk-Melody J; Owens K; Levorse D; Kim P; Schmidt JA; Mumford RA
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2709-13. PubMed ID: 11591507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imidazopyridines as VLA-4 integrin antagonists.
    Phillips DJ; Davenport RJ; Demaude TA; Galleway FP; Jones MW; Knerr L; Perry BG; Ratcliffe AJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4146-9. PubMed ID: 18539454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.
    Kamenecka TM; Lanza T; de Laszlo SE; Li B; McCauley ED; Van Riper G; Egger LA; Kidambi U; Mumford RA; Tong S; MacCoss M; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2205-8. PubMed ID: 12127538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists.
    Chiba J; Takayama G; Takashi T; Yokoyama M; Nakayama A; Baldwin JJ; McDonald E; Moriarty KJ; Sarko CR; Saionz KW; Swanson R; Hussain Z; Wong A; Machinaga N
    Bioorg Med Chem; 2006 Apr; 14(8):2725-46. PubMed ID: 16377201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists.
    Huryn DM; Ashwell S; Baudy R; Dressen DB; Gallaway W; Grant FS; Konradi A; Ley RW; Petusky S; Pleiss MA; Sarantakis D; Semko CM; Sherman MM; Tio C; Zhang L
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1651-4. PubMed ID: 15026043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
    Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
    Witherington J; Blaney EL; Bordas V; Elliott RL; Gaiba A; Garton N; Green PM; Naylor A; Smith DG; Spalding DJ; Takle AK; Ward RW
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5538-41. PubMed ID: 16931004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of acid surrogates toward potency of VLA-4 antagonist.
    Venkatraman S; Lim J; Cramer M; Gardner MF; James J; Alves K; Lingham RB; Mumford RA; Munoz B
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4053-6. PubMed ID: 16039122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
    Lin LS; Lanza TJ; Castonguay LA; Kamenecka T; McCauley E; Van Riper G; Egger LA; Mumford RA; Tong X; MacCoss M; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2004 May; 14(9):2331-4. PubMed ID: 15081035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.
    Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB
    Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
    Chiba J; Iimura S; Yoneda Y; Watanabe T; Muro F; Tsubokawa M; Iigou Y; Satoh A; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2007 Feb; 15(4):1679-93. PubMed ID: 17194595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.
    Muro F; Iimura S; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2009 Feb; 17(3):1232-43. PubMed ID: 19124247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.